802 related articles for article (PubMed ID: 26463157)
1. Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090.
Contreras-Ruiz L; Mir FA; Turpie B; Krauss AH; Masli S
Exp Eye Res; 2016 Feb; 143():1-8. PubMed ID: 26463157
[TBL] [Abstract][Full Text] [Related]
2. Improvement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model.
Krauss AH; Corrales RM; Pelegrino FS; Tukler-Henriksson J; Pflugfelder SC; de Paiva CS
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5888-95. PubMed ID: 26348638
[TBL] [Abstract][Full Text] [Related]
3. Modulation of integrin alpha4beta1 (VLA-4) in dry eye disease.
Ecoiffier T; El Annan J; Rashid S; Schaumberg D; Dana R
Arch Ophthalmol; 2008 Dec; 126(12):1695-9. PubMed ID: 19064851
[TBL] [Abstract][Full Text] [Related]
4. Topical TSG-6 Administration Protects the Ocular Surface in Two Mouse Models of Inflammation-Related Dry Eye.
Lee MJ; Kim DH; Ryu JS; Ko AY; Ko JH; Kim MK; Wee WR; Khwarg SI; Oh JY
Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5175-81. PubMed ID: 26244293
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-derived peptide attenuates Sjögren's syndrome-associated ocular surface inflammation in mice.
Contreras Ruiz L; Mir FA; Turpie B; Masli S
Clin Exp Immunol; 2017 Apr; 188(1):86-95. PubMed ID: 28033649
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome.
Shah M; Edman MC; Reddy Janga S; Yarber F; Meng Z; Klinngam W; Bushman J; Ma T; Liu S; Louie S; Mehta A; Ding C; MacKay JA; Hamm-Alvarez SF
Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):372-385. PubMed ID: 28122086
[TBL] [Abstract][Full Text] [Related]
7. Conjunctival inflammation in thrombospondin-1 deficient mouse model of Sjögren's syndrome.
Contreras-Ruiz L; Regenfuss B; Mir FA; Kearns J; Masli S
PLoS One; 2013; 8(9):e75937. PubMed ID: 24086667
[TBL] [Abstract][Full Text] [Related]
8. Lymphocytic infiltration and goblet cell marker alteration in the conjunctiva of the MRL/MpJ-Fas(lpr) mouse model of Sjögren's syndrome.
Diebold Y; Chen LL; Tepavcevic V; Ferdman D; Hodges RR; Dartt DA
Exp Eye Res; 2007 Mar; 84(3):500-12. PubMed ID: 17208228
[TBL] [Abstract][Full Text] [Related]
9. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca.
Pflugfelder SC; Jones D; Ji Z; Afonso A; Monroy D
Curr Eye Res; 1999 Sep; 19(3):201-11. PubMed ID: 10487957
[TBL] [Abstract][Full Text] [Related]
10. FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue.
Xiao W; Xu GT; Zhang J; Zhang J; Zhang Y; Ye W
Exp Eye Res; 2015 Sep; 138():145-52. PubMed ID: 26187517
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule antagonist of VLA-4 (GW559090) attenuated neuro-inflammation by targeting Th17 cell trafficking across the blood-retinal barrier in experimental autoimmune uveitis.
Chen YH; Eskandarpour M; Zhang X; Galatowicz G; Greenwood J; Lightman S; Calder V
J Neuroinflammation; 2021 Feb; 18(1):49. PubMed ID: 33602234
[TBL] [Abstract][Full Text] [Related]
12. Use of topical cyclosporin A in a primary Sjögren's syndrome mouse model.
Tsubota K; Saito I; Ishimaru N; Hayashi Y
Invest Ophthalmol Vis Sci; 1998 Aug; 39(9):1551-9. PubMed ID: 9699544
[TBL] [Abstract][Full Text] [Related]
13. Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity.
Stevenson W; Sadrai Z; Hua J; Kodati S; Huang JF; Chauhan SK; Dana R
Cornea; 2014 Feb; 33(2):177-83. PubMed ID: 24342887
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of osmoprotectants on prevention and treatment of murine dry eye.
Chen W; Zhang X; Li J; Wang Y; Chen Q; Hou C; Garrett Q
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6287-97. PubMed ID: 23970467
[TBL] [Abstract][Full Text] [Related]
15. Spdef null mice lack conjunctival goblet cells and provide a model of dry eye.
Marko CK; Menon BB; Chen G; Whitsett JA; Clevers H; Gipson IK
Am J Pathol; 2013 Jul; 183(1):35-48. PubMed ID: 23665202
[TBL] [Abstract][Full Text] [Related]
16. In vivo confocal microscopy of conjunctival goblet cells in patients with Sjogren's syndrome dry eye.
Hong J; Zhu W; Zhuang H; Xu J; Sun X; Le Q; Li G; Wang Y
Br J Ophthalmol; 2010 Nov; 94(11):1454-8. PubMed ID: 19955202
[TBL] [Abstract][Full Text] [Related]
17. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease.
Vijmasi T; Chen FY; Chen YT; Gallup M; McNamara N
Mol Vis; 2013; 19():1957-65. PubMed ID: 24068863
[TBL] [Abstract][Full Text] [Related]
18. Association between systemic activity ındex and dry eye severity in patients with primary Sjögren syndrome.
Ozek D; Kemer OE; Omma A
Arq Bras Oftalmol; 2019; 82(1):45-50. PubMed ID: 30403265
[TBL] [Abstract][Full Text] [Related]
19. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Effects of STAT3 Inhibition on Experimental Murine Dry Eye.
Qu M; Qi X; Wang Q; Wan L; Li J; Li W; Li Y; Zhou Q
Invest Ophthalmol Vis Sci; 2019 Sep; 60(12):3776-3785. PubMed ID: 31503282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
